276 related articles for article (PubMed ID: 34659899)
41. Evaluation of CML TKI Induced Cardiovascular Toxicity and Development of Potential Rescue Strategies in a Zebrafish Model.
Cheng S; Jin P; Li H; Pei D; Shu X
Front Pharmacol; 2021; 12():740529. PubMed ID: 34733159
[TBL] [Abstract][Full Text] [Related]
42. [Clinical characteristics of chronic myeloid leukemia with T315I mutation and the efficacy of ponatinib].
Chen C; Xu N; Jiang X; Wu W; Zhou X; Liu L; Huang J; Yin C; Cao R; Liao L; Xu D; Zhang Y; Liu Q; Liu X
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Mar; 39(3):364-368. PubMed ID: 31068313
[TBL] [Abstract][Full Text] [Related]
43. Investigating Potential Cardiovascular Toxicity of Two Anti-Leukemia Drugs of Asciminib and Ponatinib in Zebrafish Embryos.
Lin HC; Saputra F; Audira G; Lai YH; Roldan MJM; Alos HC; Aventurado CA; Vasquez RD; Tsai GJ; Lim KH; Hsiao CD
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233014
[TBL] [Abstract][Full Text] [Related]
44. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.
Chan WW; Wise SC; Kaufman MD; Ahn YM; Ensinger CL; Haack T; Hood MM; Jones J; Lord JW; Lu WP; Miller D; Patt WC; Smith BD; Petillo PA; Rutkoski TJ; Telikepalli H; Vogeti L; Yao T; Chun L; Clark R; Evangelista P; Gavrilescu LC; Lazarides K; Zaleskas VM; Stewart LJ; Van Etten RA; Flynn DL
Cancer Cell; 2011 Apr; 19(4):556-68. PubMed ID: 21481795
[TBL] [Abstract][Full Text] [Related]
45. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation.
Burslem GM; Schultz AR; Bondeson DP; Eide CA; Savage Stevens SL; Druker BJ; Crews CM
Cancer Res; 2019 Sep; 79(18):4744-4753. PubMed ID: 31311809
[TBL] [Abstract][Full Text] [Related]
46. Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes.
Hijiya N; Mauro MJ
Cancer Manag Res; 2023; 15():873-891. PubMed ID: 37641687
[TBL] [Abstract][Full Text] [Related]
47. Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations.
Razga F; Jurcek T; Zackova D; Dvorakova D; Toskova M; Jeziskova I; Mayer J; Racil Z
Mol Diagn Ther; 2012 Aug; 16(4):251-9. PubMed ID: 22873741
[TBL] [Abstract][Full Text] [Related]
48. A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia.
Woessner DW; Eiring AM; Bruno BJ; Zabriskie MS; Reynolds KR; Miller GD; O'Hare T; Deininger MW; Lim CS
Leukemia; 2015 Aug; 29(8):1668-75. PubMed ID: 25721898
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells.
Tanaka Y; Fukushima T; Mikami K; Adachi K; Fukuyama T; Goyama S; Kitamura T
Exp Hematol; 2020 Oct; 90():46-51.e2. PubMed ID: 32910995
[TBL] [Abstract][Full Text] [Related]
50. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.
Mauro MJ; Hughes TP; Kim DW; Rea D; Cortes JE; Hochhaus A; Sasaki K; Breccia M; Talpaz M; Ottmann O; Minami H; Goh YT; DeAngelo DJ; Heinrich MC; Gómez-García de Soria V; le Coutre P; Mahon FX; Janssen JJWM; Deininger M; Shanmuganathan N; Geyer MB; Cacciatore S; Polydoros F; Agrawal N; Hoch M; Lang F
Leukemia; 2023 May; 37(5):1048-1059. PubMed ID: 36949155
[TBL] [Abstract][Full Text] [Related]
51. Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Hoy SM
Drugs; 2014 May; 74(7):793-806. PubMed ID: 24807266
[TBL] [Abstract][Full Text] [Related]
52. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.
Khorashad JS; Kelley TW; Szankasi P; Mason CC; Soverini S; Adrian LT; Eide CA; Zabriskie MS; Lange T; Estrada JC; Pomicter AD; Eiring AM; Kraft IL; Anderson DJ; Gu Z; Alikian M; Reid AG; Foroni L; Marin D; Druker BJ; O'Hare T; Deininger MW
Blood; 2013 Jan; 121(3):489-98. PubMed ID: 23223358
[TBL] [Abstract][Full Text] [Related]
53. The molecular signature of
Baassiri A; Ghais A; Kurdi A; Rahal E; Nasr R; Shirinian M
iScience; 2024 Apr; 27(4):109538. PubMed ID: 38585663
[TBL] [Abstract][Full Text] [Related]
54. Validation of a
Outa AA; Abubaker D; Bazarbachi A; Sabban ME; Shirinian M; Nasr R
Haematologica; 2020; 105(2):387-397. PubMed ID: 31101753
[TBL] [Abstract][Full Text] [Related]
55. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
56. BCR::ABL1 Kinase N-lobe Mutants Confer Moderate to High Degrees of Resistance to Asciminib.
Leyte-Vidal A; Garrido Ruiz D; DeFilippis R; Leske IB; Rea D; Phan S; Miller KB; Hu F; Mase A; Shan Y; Hantschel O; Jacobson MP; Shah NP
Blood; 2024 Apr; ():. PubMed ID: 38643492
[TBL] [Abstract][Full Text] [Related]
57. A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib.
Tomassetti S; Lee J; Qing X
Clin Case Rep; 2022 Nov; 10(11):e6478. PubMed ID: 36381034
[TBL] [Abstract][Full Text] [Related]
58. T315I-mutated myeloid sarcoma.
Zhang Y; Swoboda DM; Grover A; Nodzon L; Zhang L; Pinilla-Ibarz J
Leuk Res Rep; 2019; 12():100184. PubMed ID: 31485411
[TBL] [Abstract][Full Text] [Related]
59. The catalytic activity of Abl1 single and compound mutations: Implications for the mechanism of drug resistance mutations in chronic myeloid leukaemia.
Georgoulia PS; Todde G; Bjelic S; Friedman R
Biochim Biophys Acta Gen Subj; 2019 Apr; 1863(4):732-741. PubMed ID: 30684523
[TBL] [Abstract][Full Text] [Related]
60. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
Gontarewicz A; Balabanov S; Keller G; Colombo R; Graziano A; Pesenti E; Benten D; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
Blood; 2008 Apr; 111(8):4355-64. PubMed ID: 18268096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]